Isatuximab - ImmunoGen/Sanofi
Alternative Names: Anti-CD38 monoclonal antibody - Sanofi; hu38SB19; Isatuximab-irfc; SAR-650984; SarclisaLatest Information Update: 09 Jun 2024
At a glance
- Originator ImmunoGen
- Developer Roche; Sanofi
- Class Antibodies; Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action ADP-ribosyl cyclase inhibitors; Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Natural killer cell stimulants; Regulatory T-lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Multiple myeloma
- Phase II Acute myeloid leukaemia; Colorectal cancer; Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
- Phase I/II Lymphoma; Solid tumours; Urogenital cancer
- Discontinued Autoimmune haemolytic anaemia; Non-small cell lung cancer; Prostate cancer; Renal transplant rejection
Most Recent Events
- 03 Jun 2024 Efficacy and adverse event data from a phase III trial in Multiple myeloma was released by Sanofi
- 27 May 2024 Preregistration for Multiple myeloma (Combination therapy, First-line therapy, Newly diagnosed) in European Union (IV)
- 27 May 2024 Preregistration for Multiple myeloma (Combination therapy, First-line therapy, Newly diagnosed) in USA (IV)